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The 50th Anniversary of the Declaration
of Helsinki
Progress but Many Remaining Challenges
Since 1964, through 7 revisions, the World Medical
Association’s (WMA’s)DeclarationofHelsinki has stood
as an important statement regarding the ethical prin-
ciples guiding medical research with human partici-
pants.Thedeclaration isconsultedbyethics reviewcom-
mittees, funders, researchers, andresearchparticipants;
has been incorporated into national legislation; and is
routinely invoked to ascertain the ethical appropriate-
ness of clinical trials.
There is much to praise about the revision process
and the latest revision, which coincides with the decla-
ration’s 50th anniversary. The Working Group exten-
sively consulted stakeholders and justified the pro-
posed revisions. The result is adeclaration that is better
organized into clear sections,moreprecise, and likely to
bemore effective at protecting research participants.
For the first time, thedeclaration requires compen-
sationand treatment for research-related injuries (para-
graph 15), an explicit recognition that research partici-
pants shouldnotbear thecostsof researchgonewrong.1
The revised declaration’s emphasis on the dissemina-
tion of research results, including studieswith negative
results, should increase the value of medical research
(paragraphs 23, 35, and 36).
Nevertheless, theproposeddeclarationcontainsper-
sistent flaws.While thedocumentpurports tobea state-
ment of enduring ethical principles, the nearly continu-
ous process of revision undermines its authority.2
Moreover, the declaration continues to assert that “con-
sistent with the mandate of theWMA,” its primary audi-
ence is physicians (paragraph 2). This is a mistake. In-
deed, the document then offers recommendations for
otherhealthprofessionals (paragraph9), researchethics
committees (paragraph 23), sponsors and governments
(paragraph34),andeditorsandpublishers(paragraph36).
It is timefor theWMAtorecognizethat theDeclarationof
Helsinkishouldaddressphysiciansaswellotherhealthpro-
fessionals and personnel involved in research. A state-
mentofethicalprinciplesdoesnotrequireamandatefrom
the peoplewho ought to follow those principles.2
Thereviseddeclaration’s treatmentof informedcon-
sent remains inadequate. It fails to recognizethepossibil-
ity of waiving consent for some research involving com-
petentadults,eventhoughsuchresearch iscommonand
widelyendorsed.Similarly, thedeclarationavoidsprovid-
ingguidanceonwhen it canbeappropriate toaskpartici-
pantstogivebroadconsent for theirbiological samplesto
beusedinawiderangeoffuturestudies, ratherthanseek-
ingconsent foreachspecific study.This isapressing issue
onwhichresearchersneedclearguidance. Inaddition, the
declarationprohibits individualswhocannotconsentfrom
participating in research thatdoesnotaddress thecondi-
tion that caused their incapacity (paragraph 30), even
whentheresearchoffersparticipantsthepotential for im-
portant medical benefit and there are no—or few—
potential participants who can consent. This approach
transforms a protection into a barrier.
ProblemsWith Research Posing Net Risks
Research studies and interventions thatpose riskswith-
out compensating benefits to participants—“nonben-
eficial” studies—arecrucial to improvingmedical care.Yet
the revised declaration offers conflicting and problem-
atic guidance on this topic. It rejects placing partici-
pants at anynet risk to collectdata, nomatterhowvalu-
able: “While the primary purpose ofmedical research is
togeneratenewknowledge, thisgoal cannever takepre-
cedence over the rights and interests of individual re-
search subjects” (paragraph 8, emphasis added).
Similarly, the declaration permits research com-
binedwithmedical care—an increasingly important cat-
egory of research— only to the extent that “this is justi-
fiedby itspotentialpreventive,diagnosticor therapeutic
value,” leaving it unclearwhether individualsmaybeex-
posedtoanynet risks inthiscontext (paragraph14).Even
more puzzling, the declaration seems to allownonben-
eficial research only with individuals who are unable to
give informed consent (paragraph 28).
Clearly, thegoalofgeneratingnewknowledgemust
not take precedence over the rights of individual re-
searchparticipants.Researchparticipants shouldnotbe
exposedtohighnet risks.Yetnonbeneficial researchcan
beethicalwhenthenet risks toparticipants’ interestsare
lowand thebenefits to society are sufficiently large. In-
deed, inapparentconflictwithparagraphs8and14,para-
graphs 16and28seemtoaffirmthatethical researchcan
pose some net risks to participants: “Medical research
involving human subjectsmay only be conducted if the
importanceof theobjectiveoutweighs the risksandbur-
dens to the research subjects” (paragraph 16).
The declaration’s lack of clear and consistent guid-
ance regardingwhennet risksareacceptablecreatesun-
necessary confusion and fuels the unfounded concern
that all medical research is inherently exploitative.
ProblemsWith Research in Poor Communities
Thedeclaration rightly recognizes the importanceofpro-
tecting the worst off, including populations who lack ac-
cesstoadequatehealthcare.Thereviseddeclarationcalls
for special protection for groups and individualswho are
“vulnerableandmayhaveanincreasedlikelihoodofbeing
wrongedorof incurringadditionalharm”(paragraph19).3
VIEWPOINT
JosephMillum, PhD
Department of
Bioethics, Clinical
Center, National
Institutes of Health,
Bethesda, Maryland,
and Fogarty
International Center,
National Institutes of
Health, Bethesda,
Maryland.
DavidWendler, PhD
Department of
Bioethics, Clinical
Center, National
Institutes of Health,
Bethesda, Maryland.
Ezekiel J. Emanuel,
MD, PhD
Office of the Provost,
University of
Pennsylvania,
Philadelphia, and
Department of Medical
Ethics and Health
Policy, Perelman School
of Medicine, University
of Pennsylvania,
Philadelphia.
Viewpoint page 2145
Related article
page 2191
Corresponding
Author: Ezekiel J.
Emanuel, MD, PhD,
Department of Medical
Ethics and Health
Policy, University of
Pennsylvania, 122
College Hall,
Philadelphia, PA 19104
(vp-global@upenn
.edu).
Opinion
jama.com JAMA November 27, 2013 Volume 310, Number 20 2143
Downloaded From: http://jama.jamanetwork.com/ by a National Institutes of Health User  on 08/25/2016
Copyright 2013 American Medical Association. All rights reserved.
It thendelineates3conditions for researchwithvulnerablegroups: (1)
the researchmust be responsive to their health needs; (2) itmust be
impossible to carryoutwithnonvulnerablegroups; and (3) thegroup
should stand to benefit from the knowledge, practices, or interven-
tions that result from the research (paragraph 20).
Thedeclaration isconfusedandmistakenaboutvulnerabilityand
appropriateprotections.4,5First, thegroupthedeclarationhas inmind
that is in need of special protections is vulnerable because they are
poor and have limited access to medical services, not because they
are at higher risk of harms. Failure tomake this clear undermines the
protections.What isnecessarytoprotectpoorpopulations isverydif-
ferentfromwhat isnecessarytoprotectparticipantswhoareathigher
risk of harm, cannot consent, or, because of their position, eg, being
a student, are at increased risk of coercion.
Secondandmore importantly, thedeclaration isconfusedabout
whatconstitutesappropriateprotectionsandtheappropriatemeans
to achieve those protections.
Tobeclearandcomprehensive, thedeclarationshouldstate that
populations who are vulnerable to exploitation should always re-
ceive a fair level of benefits. Providing fair benefits is the goal. The
means to achieve it vary. In only a limited number of clinical trials,
the requirement that vulnerable groups should benefit “from the
knowledge, practice, or interventions that result from the re-
search” (paragraph 20) along with the requirement that partici-
pants have posttrial access to interventions identified as beneficial
(paragraph 34) can provide fair benefits, but only with respect to
phase 3 trials in which an experimental intervention is found to be
more effective. When research does not prove an intervention ef-
fective—phase 1 and 2, and negative phase 3 research trials—
participants frompoor countrieswith limitedaccess tomedical ser-
vices are unlikely tobenefit at all from these requirements. In these
cases, a research project might supply clean water, new clinics, or
build local medical and research capacity. If this level of benefits is
fair, then the research will not be exploitative.
ProblemsWith Placebos
The revised declaration fails to address the testing of interventions
that may be beneficial to some groups but are expected to be less
effective than interventions that are available elsewhere—“thebest
proven interventions.” It asserts that placebos may be used only
when the “patients” who receive them “will not be subject to addi-
tional risks of seriousor irreversible harmasa result of not receiving
thebestproven intervention” (paragraph33, emphasis added).How
to interpret this last clause is unclear. The danger is that itmay pre-
clude vital research that promises to improve the condition of the
worst off. For example, past trials of single-dosenevirapinegiven to
mothersduring labor and their infantswithin 72hoursofbirthdem-
onstrated that this approach was a highly cost-effective means of
reducing mother-to-child-transmission of HIV.6 However, it was
known at the time that single-dose nevirapine would not be as ef-
fective as more comprehensive and much more expensive treat-
ment regimens that also targeted transmission during pregnancy.
Yet trials that used less than the best-known treatment were ethi-
cal and had the potential to benefit mothers who otherwise would
receive nothing. A future and better declaration should allow such
trials under strict conditions, especially when no patients are de-
prived of treatment they would otherwise receive and the re-
search has the potential to save lives and improve the care of poor
populations.7
Conclusion
The revisedDeclarationofHelsinki representsa significant improve-
ment over previous versions. Creating an international document
to guide research around the world is an enormously difficult and
complicated task.Nevertheless, importantproblemsandsomecon-
fusion remain in this 50th-anniversary declaration. The definitive
guidance on research ethics and even better protection for re-
search participants await responses to theDeclaration ofHelsinki’s
remaining challenges.
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